Aligos Therapeutics, Inc. (ALGS)

In August 2025, Aligos Therapeutics dosed the first patient in its Phase 2 B-SUPREME study for pevifoscorvir sodium. On November 6, 2025, the company reported a net loss of $31.5 million for Q3 2025, compared to a net loss of $19.3 million for the same period in 2024, with research and development expenses increasing to $23.9 million. The company's stock price as of January 29, 2026, was $8.12, a 65.82% decrease from $23.74 on January 30, 2025, and has traded between $29.54 and $3.76 over the past 52 weeks.

Information regarding specific demand seasonality for Aligos Therapeutics, Inc.'s products and services is not readily available. As a clinical-stage biopharmaceutical company, its current focus is on drug discovery and development, rather than commercial product sales, which typically exhibit demand seasonality.

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapeutics for chronic liver diseases and viral infections, including chronic hepatitis B (CHB), metabolic dysfunction-associated steatohepatitis (MASH), and coronaviruses. Key product candidates include ALG-055009, a small molecule THR-ß agonist in Phase 2a clinical trials for MASH; pevifoscorvir sodium, a capsid assembly modulator in Phase 2 clinical study for CHB; ALG-125755, a siRNA drug candidate in Phase 1 clinical trials for CHB; and ALG-097558, a drug candidate in Phase 2 clinical trials for coronavirus. The company also has an ASO platform for chronic hepatitis B and is developing a novel strategy for hepatitis delta virus (HDV) infection.

Aligos Therapeutics, Inc. is headquartered in South San Francisco, California, United States.

Aligos Therapeutics has a consensus "Hold" rating from analysts, with an average rating score of 2.33, based on two "Buy" ratings and one "Sell" rating. The company's management presented at the Jefferies London Healthcare Conference on November 17, 2025, and the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025.

Aligos Therapeutics, Inc. has 40 institutional owners and shareholders holding a total of 2,664,726 shares. Institutional ownership accounted for 19.47% of common stock held, while hedge fund managers held 19.76% as of September 30, 2025.